Therefore, the lncRNAHOTAIR-miR126-DNMT1-CDKN2A axis was proposed to be a novel therapeutic alternative, especially targeting HOTAIR due to its potential to increase osteosarcoma chemosensitivity toward DNMT1 inhibitors (Li et al., 2017b). Here, DNMT1 is linked to osteosarcoma.